| Document Date: 2014-10-01 09:05:22
Open Document File Size: 281,62 KBShare Result on Facebook
City FUKUOKA / / Company AEs / Intravenous Solutions / Sagent Pharmaceuticals Inc. / Ames / / Country United States / India / / Event FDA Phase / / Facility Storage Conditions Store / / IndustryTerm injection solution / aqueous solution / drug products / / MedicalCondition Chest Pain / headache / rodent tumor / Leukopenia / nausea / thrombocytopenia / rhinitis / Alopecia / tremor / ifosfamide-induced hemorrhagic cystitis / Fatigue / WARNINGS Allergic reactions / tachycardia / Granulocytopenia / diarrhea / constipation / hypotension / Abdominal Pain / autoimmune disorders / Insomnia / hypertension / flushing / Dyspnea / hematuria / Carcinogenesis / coughing / erythema / fever / pain / Surveillance Allergic reactions / vomiting / concomitant disease / systemic anaphylactic reactions / allergic reactions / Mesna Patients Developing Hematuria / IV Mesna Hemorrhagic cystitis / mild hypersensitivity / dizziness / Hypokalemia / pharyngitis / Anemia / hemorrhagic cystitis / / MedicalTreatment chemotherapy / drug therapy / / Organization World Health Organization / DOSAGE AND ADMINISTRATION / FDA / / / Product Mesna / carboplatin / cisplatin / Sodium Chloride / cyclophosphamide / Dextrose / ifosfamide / edetate disodium / acetic acid / Mesna injection / / ProvinceOrState Illinois / / Technology Geriatrics / Pharmacokinetics / chemotherapy / GSM / / URL www.fda.gov/medwatch / /
SocialTag |
Mesna Injection 100 mg per mL IV-IV-IV Regimen After intravenous administration of an 800-mg dose, the half-lives of mesna and dimesna in the blood are 0.36 hours and 1.17 hours, respectively. Approximately 32% and 33%